Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYCassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s DiseasePREV STORYFoghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference